Clinical Trial Update: Validation of ERTugliflozin for Inhibiting Cardiac Fibrosis Using Cardiac MRI and Laboratory Parameters in Korean Heart Failure Patients With Nonischemic Cardiomyopathy(VERTICAL) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating ERTugliflozin for reducing cardiac fibrosis in Korean patients with nonischemic cardiomyopathy, using cardiac MRI and l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Nonischemic Cardiomyopathy

Drugs mentioned

• Ertugliflozin (ertugliflozin)

Snippet

Sponsor: Yonsei University | Conditions: Heart Failure With Nonischemic Cardiomyopathy | Phase 3 | Status: UNKNOWN